Fatigue syndrome in chronic neurological disorders;Zespół zmeczenia w przewlekłych chorobach neurologicznych

Neurologia i Neurochirurgia Polska

Volumn 41, Issue 4, 2007, Pages 340-349

  Brola, Waldemar ^a   Ziomek, Małgorzata ^a   Czernicki, Jan ^b  

^a Szpital Specjalistyczny ^*  (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Aetiology; Diagnosis; Fatigue; Nervous system diseases; Therapy

Indexed keywords

AMANTADINE; BENZODIAZEPINE DERIVATIVE; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MODAFINIL; NORADRENALIN; OPIATE; PEMOLINE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

CHRONIC FATIGUE SYNDROME; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; MACROGLIA; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PSYCHOTHERAPY; REVIEW; RISK FACTOR;

CHRONIC DISEASE; DEPRESSION; FATIGUE; HUMANS; MENTAL FATIGUE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE; POSTPOLIOMYELITIS SYNDROME; STROKE;

EID: 34848907390     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Chaudhuri A., Behan P.O. Fatigue and basal ganglia. J Neurol Sci 2000; 179: 34-42.
2. Krupp L.B., Pollina D.A. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 1996; 9: 456-460.
3. Schapiro R.T. Managing symptoms of multiple sclerosis. Neurol Clin 2005; 23: 177-187.
4. Członkowska A. Stwardnienie rozsiane - współczesna diagnostyka i leczenie. Przew Lek 2003; 6: 6-15.
5. McEwen B.S. Protective and damaging effects of stress mediators. N Engl J Med 1998; 33 8: 171-179.
6. Krupp L.B., Alvarez L.A., LaRocca N.G. i wsp. Clinical characteristics of fatigue in multiple sclerosis. Arch Neurol 1988; 45: 435-437.
7. Ford H., Trigwell P, Johnson M. The nature of fatigue in multiple sclerosis. J Psychosom Res 1998; 45: 33-38.
8. Comi G., Leocani L., Rossi P. i wsp. Pathophysiology and treatment of fatigue in multiple sclerosis. J Neurol 2001; 248: 174-179.
9. Bruno R.L., Sapolsky R., Zimmerman J.R. i wsp. The pathophysiology of a central cause of post-polio fatigue. Ann N Y Acad Sci 1995; 753: 257-275.
10. Bruno R.L., Galaski T., DeLuca J. The neuropsychology of post-polio fatigue. Arch Phys Med Rehabil 1993; 74: 1061-1065.
11. Scott L.V., Dinan T.G. The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis. Funct Neurol 1999; 14: 3-11.
12. Kelley K.W., Bluthe R.M., Dantzer R. i wsp. Cytokine-induced sickness behavior. Brain Behav Immun 2003; 17 Suppl 1: S112-S118.
13. Heesen C., Nawrath L., Reich C. i wsp. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosarg Psychiatry 2006; 77: 34-39.
14. Rönnbäck L., Hansson E. On the potential role of glutamate transport in mental fatigue. J Neuroinflammation 2004; 1: 22.
15. Bałkowiec-Iskra E., Niewada M. Zespół przewlekłego zmeczenia - postepy leczenia. Przew Lek 2002; 5: 16-22.
16. Chaudhuri A., Behan W.M., Behan P.O. Chronic fatigue syndrome. Proc R Coll Physicians Edinb 1998; 28: 150-163.
17. Krupp L.B., Elkins L.E. Fatigue and declines in cognitive functioning in multiple sclerosis. Neurology 2000; 55: 934-939.
18. Latash M., Kalugina E., Nicholas J. i wsp. Myogenic and central neurogenic factors in fatigue in MS. Mult Scler 1996; 1: 236-241.
19. Filippi M., Rocca M.A., Colombo B. i wsp. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 2002; 15: 559-567.
20. Djaldetti R., Ziv I., Achiron A. i wsp. Fatigue in multiple sclerosis compared with chronic fatigue syndrome: a quantitative assessment. Neurology 1996; 46: 632-635.
21. Colle F., Bonan I., Gelez Leman M.C. i wsp. Fatigue after stroke. Ann Readapt Med Phys 2006; 49: 361-364.
22. Staub F., Bogousslavsky J. Fatigue after stroke: a major but neglected issue. Cerebrovasc Dis 2001; 12: 75-81.
23. Ingles J.L., Eeskes G.A., Philips S.J. Fatigue after stroke. Arch Phys Med Rehabil 1999; 80: 173-178.
24. Glader E., Stegmayr B., Asplund K. Poststroke fatigue: a 2-year follow-up study of stroke patients in Sweden. Stroke 2002; 33: 1327-1333.
25. van der Werf S.P., van den Broek H.L, Anten H.W. Experience of severe fatigue long after stroke and its relation to depressive symptoms and disease characteristics. Eur Neurol 2001; 45: 28-33.
26. Choi-Kwon S., Han S.W., Kwon S.U. i wsp. Poststroke fatigue: characteristics and related factors. Cerebrovasc Dis 2005; 19: 84-90.
27. De Groot M.H., Phillips S.J., Eskes G.A. Fatigue associated with stroke and other neurologic conditions: Implications for stroke rehabilitation. Arch Phys Med Rehabil 2003; 84: 1714-20.
28. Staub F., Bogousslavsky J. Post-stroke depression or fatigue? Eur Neurol 2001; 45: 3-5.
29. Schepers V.P., Visser-Meily A.M., Ketelaar M. i wsp. Poststroke fatigue: course and its relation to personal and stroke-related factors. Arch Phys Med Rehabil 2006; 87: 184-188.
30. Naess H., Nyland H.I., Thomassen L. i wsp. Fatigue at long-term follow-up in young adults with cerebral infarction. Cerebrovasc Dis 2005; 20: 245-250.
31. van Zandvoort M., de Haan E., van Gijn J. i wsp. Cognitive functioning in patients with a small infarct in the brain stem. J Int Neuropsychol Soc 2003; 9: 490-494.
32. Jaracz K., Mielcarek M., Kozubski W. Kliniczne i psychologiczne uwarunkowania zmeczenia po udarze mózgu. Wyniki wstepne. Neurol Neurochir Pol 2007; 41: 36-43.
33. Bruno R.L., Crenage S.J., Fick N.M. Parallels between post-polio fatigue and chronic fatigue syndrome: a common pathophysiology? Am J Med 1998; 105: 66-73.
34. Karlsen K., Larsen J.P., Tandberg E. i wsp. Fatigue in patients with Parkinson's disease. Mov Disord 1999; 14: 237-241.
35. Friedman J., Friedman H. Fatigue in Parkinson's disease. Neurology 1993; 43: 2016-2018.
36. Hitten J.J., van Hoogland G., van der Velde E.A. i wsp. Diurnal effects of motor activity and fatigue in Parkinson's disease. J Neurol Neurosurg Psychiatry 1993; 56: 874-877.
37. Pozo-Rosich P., Clover L., Saiz A. i wsp. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 2003; 54: 530-533.
38. Bradley L.A., Alarcon G.S. Is Chiari malformation associated with increased levels of substance P and clinical symptoms in persons with fibromyalgia? Arthritis Rheum 1999; 60: 471-473.
39. Garssen M.P., Bussmann J.B., Schmitz P.I. i wsp. Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP. Neurology 2004; 63: 2393-2395.
40. Sharma K.R., Kent-Braun J.A., Majumdar S. i wsp. Physiology of fatigue in amyotrophic lateral sclerosis. Neurology 1995; 45: 733-740.
41. Sharma K.R., Mynhier M.A., Miller R.G. Muscular fatigue in Duchenne muscular dystrophy. Neurology 1995; 45: 306-310.
42. Chaudhuri A., Behan P.O. Neurological dysfunction in chronic fatigue syndrome. J Chroxic Fatigue Syndr 2000; 6: 51-68.
43. Dittner A.J., Wessely S.C., Brown R.G. The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res 2004; 56: 157-170.
44. Schwartz J., Jandorf L., Krupp L.B. The measurement of fatigue: a new scale. J Psychosom Res 1993; 37: 753-762.
45. Krupp L.B., LaRocca N.G., Muir-Nash J. i wsp. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123.
46. Iriarte J., Katsamakis G., de Castro P. The fatigue descriptive scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Mult Scler 1999; 5: 10-16.
47. Petajan J.H., Gappmaier E., White A.T. i wsp. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996; 39: 432-441.
48. Romberg A., Virtanen A., Ruutiainen J. i wsp. Effects of a 6-month exercise program on patients with multiple sclerosis: a randomized study. Neurology 2004; 14; 63: 2034-2038.
49. van den Berg M., Dawes H., Wade D.T. i wsp. Treadmill training for individuals with multiple sclerosis: a pilot randomised trial. J Neurol Neurosurg Psychiatry 2006; 77: 531-533.
50. Mostert S., Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 2002; 8: 161-168.
51. Prins J.B., Bleijenberg G., Bazelmans E. i wsp. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet 2001; 357: 841-847.
52. Deale A., Chalder T, Marks I. i wsp. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Am J Psychiatry 1997; 154: 408-414.
53. Murray T.J. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1995; 12: 251-254.
54. Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987; 14: 273-278.
55. Geisler M.W., Stiwinski M., Coyle P.K. i wsp. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996; 53: 185-188.
56. Stein D.P., Dambrosia J.M., Dalakas M.C. A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Ann N Y Acad Sci 1995; 753: 296-302.
57. Kraft G.H., Bowen J. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005; 65: 1995-1997.
58. Willoughby E. Modafinil for fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 150.
59. Zifko U.A., Rupp M., Schwarz S. i wsp. Modafinil in treatment of fatigue in multiple sclerosis: results of an open-label study. J Neurol 2002; 249: 983-987.
60. Stankoff B., Waubant E., Confavreux C. i wsp. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005; 64: 1139-1143.
61. Branas P., Jordan R., Fry-Smith A. i wsp. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000; 4: 1-61.
62. Rossini P.M., Pasqualetti P., Pozzilli C. i wsp. Fatigue in progressive multiple sclerosis: results of a randomized double-blind, placebo-controlled, crossover trial of oral 4-aminopirydine. Mult Scler 2001; 7: 354-358.
63. Trojan D.A., Cashman N.R. An open trial of pyridostigmine in postpoliomyelitis syndrome. Can J Neurol Sci 1995; 22: 223-227.
64. Wingerchuk D.M., Benarroch E.E., O'Brien P.C. i wsp. A randomized controlled placebo crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005; 64: 1267-1269.